Technologies available for licensing, investment, joint ventures and R&D contracts in Ukraine, Azerbaijan, Georgia, Moldova, Uzbekistan

Frontpage Slideshow (version 2.0.0) - Copyright © 2006-2008 by JoomlaWorks

Google Translate

Patenting Information

Tag Cloud



Free counters!

Home Moldova Technologies Nano-encapsulation of ANTI-TB drugs for targeted delivery

Nano-encapsulation of ANTI-TB drugs for targeted delivery

Description

Tuberculosis is one of the world’s deadliest infectious diseases; killing 1.5 million people worldwide, each year.

Major problems connected with tuberculosis treatment are: strong side effects of the majority of existing anti-tuberculosis drugs; long duration of treatments; high drug dosages; unpleasant organoleptic properties; and high frequency of administration. These factors very often cause, in the patient, lack of compliance with the treatment. This fact, in association with low bioavailability and insufficient enantiomeric purity of some anti-tuberculosis drugs, can lead to the development of TB in drug-resistant (DRTB), multiple drug-resistant (MDRTB), and extensively drug-resistant (XTRB) forms.

The group of scientists involved in this project proposed to obtain new, nano-encapsulated anti-tuberculosis remedies; with higher efficiency and fewer side effects than existing drugs. The project resolves existing problems by identifying new, active anti-tuberculosis substances that are encapsulated in cyclodextrins. Cyclodextrins promote the penetration of anti-tuberculosis substances into mycobacterial cells. The nano-encapsulated drugs are loaded into alginate-chitosan microparticles, which help them penetrate into macrophages infected with M. tuberculosis.

Preliminary results from biological tests on anti-mycobacterial activity of the obtained substances and systems have demonstrated that anti-tuberculosis efficiency of these substances change in association with different cyclodextrins. Thus, β-cyclodextrin, one of the naturally occurring cyclodextrins, seems to enhance antituberculosis activity of the associated oxadiazole derivative; while sulfobutyl ether of β-cyclodextrin does not have this influence.

This observation can be explained by the fact that sulfobutyl ether of β-cyclodextrin molecule is charged due to the presence of sulfobutyl ether groups that make it less suitable for cholesterol complexation in comparison to unsubstituted β-cyclodextrin. Thus, cholesterol complex ation by cyclodextrins plays a key role in the penetration of anti-tuberculosis compounds through mycobacterial cell wall.

Contact Details

Macaev Fliur Zainutdin, Doctor
Organization: Institute of Chemistry of ASM
Address: Academy 3, Chisinau 2028, Moldova
(+373.22) 739754
This e-mail address is being protected from spambots. You need JavaScript enabled to view it ; This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Add comment


Security code
Refresh